Paul-Henry Schmelck
No más puestos en curso
Perfil
Dr. Paul-Henry Schmelck, MD, is Directeur de Participations at OTC Asset Management SA in France.
He received his doctorate degree from Université Paris, and a graduate degree from Université Paris.
Antiguos cargos conocidos de Paul-Henry Schmelck.
| Empresas | Cargo | Fin |
|---|---|---|
Ambrilia Biopharma, Inc.
 Ambrilia Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Ambrilia Biopharma, Inc. discovers and develops novel treatments for viral diseases and cancer. Its product portfolio is comprised of oncology and antiviral assets, including two new formulations of existing peptides for cancer treatment, a targeted delivery technology for cancer, an HIV protease inhibitor program as well as HIV integrase and entry inhibitors, Hepatitis C virus inhibitors and anti-Influenza A compounds. The company was founded on November 27, 1986 and is headquartered in Montréal, Canada. | Director/Miembro de la Junta | 08/03/2010 |
Apicap SAS
 Apicap SAS Investment ManagersFinance Apicap SAS is a Venture Capital firm, a subsidiary of OTC Holding SAS founded in 2001. Apicap SAS is headquartered in Paris. | Inversor de Capital Privado | 01/10/2009 |
PrimeBioTech
 PrimeBioTech Medical DistributorsDistribution Services PrimeBioTech develops therapeutic products based on gene therapy technologies. The private company is based in Paris, France. | Presidente | 01/01/2004 |
| NANOBIOTIX | Corporate Officer/Principal | - |
| NEOVACS | Director/Miembro de la Junta | - |
Formación de Paul-Henry Schmelck.
| Université Paris 1 Panthéon-Sorbonne | Doctorate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 3 |
|---|---|
| SANOFI | Health Technology |
| NEOVACS | Health Technology |
| NANOBIOTIX | Health Technology |
| Empresas privadas | 3 |
|---|---|
Apicap SAS
Apicap SAS Investment ManagersFinance Apicap SAS is a Venture Capital firm, a subsidiary of OTC Holding SAS founded in 2001. Apicap SAS is headquartered in Paris. | Finance |
Ambrilia Biopharma, Inc.
Ambrilia Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Ambrilia Biopharma, Inc. discovers and develops novel treatments for viral diseases and cancer. Its product portfolio is comprised of oncology and antiviral assets, including two new formulations of existing peptides for cancer treatment, a targeted delivery technology for cancer, an HIV protease inhibitor program as well as HIV integrase and entry inhibitors, Hepatitis C virus inhibitors and anti-Influenza A compounds. The company was founded on November 27, 1986 and is headquartered in Montréal, Canada. | Health Technology |
PrimeBioTech
PrimeBioTech Medical DistributorsDistribution Services PrimeBioTech develops therapeutic products based on gene therapy technologies. The private company is based in Paris, France. | Distribution Services |
- Bolsa de valores
- Insiders
- Paul-Henry Schmelck
